Cardiac autonomic testing and diagnosing heart disease. “A clinical perspective”

Heart International

Volumn 9, Issue 2, 2014, Pages 37-44

  DePace, Nicholas L ^a   Mears, Joy P ^b   Yayac, Michael ^a   Colombo, Joseph ^c  

^a DREXEL UNIVERSITY   (United States)

^b EASTERN UNIVERSITY   (United States)

^c Ansar Inc   (United States)

Author keywords

Cardiac autonomic neuropathy; Cardiovascular risk factors; Heart disease; Mortality

Indexed keywords

C REACTIVE PROTEIN;

ATHEROSCLEROSIS; AUTONOMIC DYSFUNCTION; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEUROPATHY; FRAMINGHAM RISK SCORE; HEART LEFT VENTRICLE FAILURE; HEART RATE VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; RESPIRATORY SINUS ARRHYTHMIA; REVIEW; RISK ASSESSMENT; SILENT MYOCARDIAL INFARCTION; SUDDEN CARDIAC DEATH;

EID: 84939222707     PISSN: 18261868     EISSN: 20362579     Source Type: Journal    
DOI: 10.5301/heartint.5000218     Document Type: Review

References (97)

1. Rosamond W, Flegal K, Furie K, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke Statistics—2008 update. Circulation. 2008;117(4):e25-e146.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al.; WRITING GROUP MEMBERS; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.
3. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197.
4. U.S. Department of Health and Human Services (HHS). Prevention Makes Common “Cents.” U.S. Department of Health and Human Services, 2003 Sep: 35 p.
5. Ausubel JH, Meyer PS, Wernick IK. Death and the human environment: the United States in the 20th century. Technol Soc. 2001;23(2):131-146.
6. Bangalore S, Steg G, Deedwania P, et al.; REACH Registry Investigators. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340-1349.
7. Kumar V, Abbas AK, Fausto N, Mitchell RS, eds. Robbins basic pathology. 8th ed. Philadelphia, PA: Saunders Elsevier; 2007:345.
8. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279-281.
9. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
11. Meigs JB, Larson MG, D’Agostino RB, et al. Coronary artery calcification in type 2 diabetes and insulin resistance: the Framingham offspring study. Diabetes Care. 2002;25(8):1313-1319.
12. Karim R, Hodis HN, Detrano R, Liu CR, Liu CH, Mack WJ. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008;102(7):825-830.
13. Kannel WB, Evans JC, Piper S, Murabito JM. Angina pectoris is a stronger indicator of diffuse vascular atherosclerosis than intermittent claudication: Framingham study. J Clin Epidemiol. 2008;61(9):951-957.
14. Oyama N, Gona P, Salton CJ, et al. Differential impact of age, sex, and hypertension on aortic atherosclerosis: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2008;28(1):155-159.
15. Junyent M, Zambón D, Gilabert R, Núñez I, Cofán M, Ros E. Carotid atherosclerosis and vascular age in the assessment of coronary heart disease risk beyond the Framingham Risk Score. Atherosclerosis. 2008;196(2):803-809.
16. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243-2251, 4p, 2251.
17. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-1908.
18. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score. Circulation. 2003;108(2):161-165.
19. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem. 2001;47(3):418-425.
20. Visonà A, Pesavento R, Lusiani L, et al. Intimal medial thickening of common carotid artery as indicator of coronary artery disease. Angiology. 1996;47(1):61-66.
21. Murphy TP, Dhangana R, Pencina MJ, D’Agostino RB. Ankle– brachial index and cardiovascular risk prediction: an analysis of 11,594 individuals with 10-year follow-up. Atherosclerosis. 2012;220(1):160-167.
22. Grayburn PA. Interpreting the coronary-artery calcium score. N Engl J Med. 2012;366(4):294-296.
23. Curtis BM, O’Keefe JH. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc. 2002;77(1):45-54.
24. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387-397.
25. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005;11(9):693-699.
26. Fantoni C, Raffa S, Regoli F, et al. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure. J Am Coll Cardiol. 2005;46(10):1875-1882.
27. Chen PS, Chou CC, Tan AY, et al. The mechanisms of atrial fibrillation. J Cardiovasc Electrophysiol. 2006;17(s3)(Suppl 3):S2-S7.
28. Copie X, Lamaison D, Salvador M, et al.; VALID Investigators. Heart rate variability before ventricular arrhythmias in patients with coronary artery disease and an implantable cardioverter defibrillator. Ann Noninvasive Electrocardiol. 2003;8(3):179-184.
29. Alter P, Grimm W, Vollrath A, Czerny F, Maisch B. Heart rate variability in patients with cardiac hypertrophy—relation to left ventricular mass and etiology. Am Heart J. 2006;151(4):829-836.
30. Debono M, Cachia E. The impact of Cardiovascular Autonomic Neuropathy in diabetes: is it associated with left ventricular dysfunction? Auton Neurosci. 2007;132(1-2):1-7.
31. Just H. Peripheral adaptations in congestive heart failure: a review. Am J Med. 1991;90(5)(5B):23S-26S.
32. Nakamura K, Matsumura K, Kobayashi S, Kaneko T. Sympathetic premotor neurons mediating thermoregulatory functions. Neurosci Res. 2005;51(1):1-8.
33. Manfrini O, Morgagni G, Pizzi C, Fontana F, Bugiardini R. Changes in autonomic nervous system activity: spontaneous versus balloon- induced myocardial ischaemia. Eur Heart J. 2004;25(17): 1502-1508.
34. Clarke BF, Ewing DJ, Campbell IW. Diabetic autonomic neuropathy. Diabetologia. 1979;17(4):195-212.
35. Eckberg DL. Physiological basis for human autonomic rhythms. Ann Med. 2000;32(5):341-349.
36. Brown TE, Beightol LA, Koh J, Eckberg DL. Important influence of respiration on human R-R interval power spectra is largely ignored. J Appl Physiol (1985). 1993;75(5):2310-2317.
37. Novak V, Novak P, de Champlain J, Le Blanc AR, Martin R, Nadeau R. Influence of respiration on heart rate and blood pressure fluctuations. J Appl Physiol (1985). 1993;74(2):617-626.
38. Parati G, Rizzoni D. Assessing the prognostic relevance of blood pressure variability: discrepant information from different indices. J Hypertens. 2005;23(3):483-486.
39. DePace NL, Mears JP, Yayac M, Colombo J. Cardiac autonomic testing and treating heart disease. “A clinical perspective.” Heart Int. 2014; 9(2):45-52.
40. Fathizadeh P, Shoemaker WC, Wo CC, Colombo J. Autonomic activity in trauma patients based on variability of heart rate and respiratory rate. Crit Care Med. 2004;32(6):1300-1305.
41. Vinik AI, Maser RE, Nakave AA. Diabetic cardiovascular autonomic nerve dysfunction. US Endocrine Disease. 2007; Dec: 2-9.
42. Vinik AI, Murray GL. Autonomic neuropathy is treatable. US Endocrinol. 2008;2:82-84.
43. Umetani K, Singer DH, McCraty R, Atkinson M. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over nine decades. J Am Coll Cardiol. 1998;31(3):593-601.
44. Cammann H, Michel J. How to avoid misinterpretation of heart rate variability power spectra? Comput Methods Programs Biomed. 2002;68(1):15-23.
45. Badra LJ, Cooke WH, Hoag JB, et al. Respiratory modulation of human autonomic rhythms. Am J Physiol Heart Circ Physiol. 2001;280(6):H2674-H2688.
46. Hayano J, Mukai S, Sakakibara M, Okada A, Takata K, Fujinami T. Effects of respiratory interval on vagal modulation of heart rate. Am J Physiol. 1994;267(1 Pt 2):H33-H40.
47. Malik M; Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93(5): 1043-1065.
48. Malik M, Bigger JT, Camm AJ, et al.; Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J. 1996;17(3):354-381.
49. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 1981;213(4504):220-222.
50. Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ. Hemodynamic regulation: investigation by spectral analysis. Am J Physiol. 1985;249(4 Pt 2):H867-H875.
51. Akselrod S, Eliash S, Oz O, Cohen S. Hemodynamic regulation in SHR: investigation by spectral analysis. Am J Physiol. 1987;253(1 Pt 2):H176-H183.
52. Akselrod S. Spectral analysis of fluctuations in cardiovascular parameters: a quantitative tool for the investigation of autonomic control. Trends Pharmacol Sci. 1988;9(1):6-9.
53. Aysin B, Aysin E. Effect of respiration in heart rate variability (HRV) analysis. Conf Proc IEEE Eng Med Biol Soc. 2006;1:1776-1779.
54. Aysin B, Aysin E. Colombo J. Comparison of HRV analysis methods during orthostatic challenge: HRV with respiration or without? IEEE Engineering in Medicine and Biology Conference. Lyons, France, 2007.
55. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818-828.
56. Pop-Busui R, Evans GW, Gerstein HC, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(7):1578-1584.
57. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(4):721-727.
58. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26(6):1895-1901.
59. Tsuji H, Venditti FJ Jr, Manders ES, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90(2):878-883.
60. Barakat HA, Mooney N, O’Brien K, et al. Coronary heart disease risk factors in morbidly obese women with normal glucose tolerance. Diabetes Care. 1993;16(1):144-149.
61. Ziegler D, Zentai CP, Perz S, et al.; KORA Study Group. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care. 2008;31(3):556-561.
62. Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving HH. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29(2):334-339.
63. Istenes I, Keresztes K, Hermányi Z, et al. Relationship between autonomic neuropathy and hypertension—are we underestimating the problem? Diabet Med. 2008;25(7):863-866.
64. Astrup AS, Nielsen FS, Rossing P, et al. Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study. J Hypertens. 2007;25(12):2479-2485.
65. Bilchick KC, Fetics B, Djoukeng R, et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs’ Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol. 2002;90(1):24-28.
66. Batchvarov V, Hnatkova K, Ghuran A, Poloniecki J, Camm AJ, Malik M. Ventricular gradient as a risk factor in survivors of acute myocardial infarction. Pacing Clin Electrophysiol. 2003;26 (1 Pt 2):373-376.
67. Ghuran A, Reid F, La Rovere MT, et al.; ATRAMI Investigators. Heart rate turbulence-based predictors of fatal and nonfatal cardiac arrest (The Autonomic Tone and Reflexes After Myocardial Infarction substudy). Am J Cardiol. 2002;89(2):184-190.
68. Barthel P, Bauer A, Müller A, et al. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care. 2011;34(8): 1833-1837.
69. Liao D, Cai J, Rosamond WD, et al. Cardiac autonomic function and incident coronary heart disease: a population-based casecohort study. The ARIC Study. Atherosclerosis Risk in Communities Study. Am J Epidemiol. 1997;145(8):696-706.
70. Huikuri HV, Jokinen V, Syvänne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19(8):1979-1985.
71. Wackers FJT, Young LH, Inzucchi SE, et al.; Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27(8):1954-1961.
72. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al.; American Heart Association Prevention Committee of the Council on Cardiovascular Nursing; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American Psychiatric Association. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118(17):1768-1775.
73. Low P, ed. Clinical autonomic disorders: evaluation and management. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1997.
74. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26(5):1553-1579.
75. Malik M, ed. Clinical guide to cardiac autonomic tests. Kluwer Academic Publishers, Dordrecht, Netherlands; 1998.
76. Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular effects in diabetic autonomic neuropathy and prognostic implications. Ann Intern Med. 1980;92(2 Pt 2):308-311.
77. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care. 2010;33(7):1688-1690.
78. Vinik AI, Maser RE, Ziegler D. Autonomic imbalance: prophet of doom or scope for hope? Diabet Med. 2011;28(6):643-651.
79. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105(22):2595-2599.
80. Su S, Lampert R, Zhao J, et al. Pleiotropy of C-reactive protein gene polymorphisms with C-reactive protein levels and heart rate variability in healthy male twins. Am J Cardiol. 2009;104(12): 1748-1754.
81. Gerstein HC, Mann JFE, Yi Q, et al.; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4): 421-426.
82. Hermans MMH, Henry R, Dekker JM, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn Study. J Am Soc Nephrol. 2007;18(6):1942-1952.
83. Hermans MMH, Henry RMA, Dekker JM, Nijpels G, Heine RJ, Stehouwer CDA. Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study. J Hypertens. 2008;26(4):791-797.
84. Fauci AS, Braunwald E, Kasper DL, et al. Harrison’s principles of internal medicine. 17th ed. New York, NY: McGraw-Hill Professional; 2008.
85. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104 (18):2158-2163.
86. Burke AP, Farb A, Malcom GT, Liang Y, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation. 1998;97(21):2110-2116.
87. Centers for Disease Control and Prevention (CDC). Decline in deaths from heart disease and stroke—United States, 1900- 1999. MMWR Morb Mortal Wkly Rep. 1999;48(30):649-656.
88. Myerburg RJ. Scientific gaps in the prediction and prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 2002;13(7): 709-723.
89. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation. 2004;110(5):522-527.
90. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the population: the Paris Prospective Study I. Circulation. 1999;99(15):1978-1983.
91. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330(15):1041-1046.
92. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana JP, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J. 2005;26(20):2142-2147.
93. Kannel WB, Cupples LA, D’Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J. 1987;113(3):799-804.
94. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006;47(6):1161-1166.
95. Buxton AE, Ellison KE, Kirk MM, et al. Primary prevention of sudden cardiac death: trials in patients with coronary artery disease. J Interv Card Electrophysiol. 2003;9(2):203-206.
96. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetière P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005;352(19):1951-1958.
97. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341(18):1351-1357.